Monday, July 7th, 2025

Private Market Boom Builds IPO Pipeline as Late-Stage Startups Attract Billions

A new wave of blockbuster initial public offerings (IPOs) could be on the horizon as an expanding pool of late-stage growth companies remain private longer, amassing value through secondary share sales and rising institutional interest.

“You’re winding up a coil,” said John Collmer, global head of private placements at Citigroup, describing the growing pipeline of high-calibre companies readying for public debut. “You are creating this massive backlog of quality companies that will go public.”

Speaking on the sidelines of Citigroup’s Private Company Growth Conference in New York, Collmer noted that institutional investors are becoming increasingly active in private placements, eager to tap into fast-evolving sectors such as artificial intelligence (AI), robotics, and defence tech — industries with limited representation in public markets.


Appetite for Private Tech Surges

The rebound in private funding in 2025 comes after a lull triggered by the Federal Reserve’s rate hikes in 2022, which dampened valuations and dried up liquidity across tech sectors. But with transformative technologies surging back into focus, investors are seeking pre-IPO access to future giants.

“Fifteen years ago, it was Uber that investors couldn’t touch in public markets,” Collmer said. “Today it’s AI, robotics, defence tech – and the disruptors are all still private.”

Leading the trend are names like SpaceX, OpenAI, Stripe, and Databricks, which have used secondary stock sales to unlock liquidity for employees and early backers. The private secondary market has swelled to US$60 billion, up from US$50 billion in 2024, according to Pitchbook.

In one recent deal, fintech startup Ramp Business allowed early stakeholders to sell US$150 million worth of shares in a transaction that valued the company at US$13 billion.


Early Signs of IPO Activity

Despite the secondary boom, public listings remain an eventual goal. According to Cully Davis, Citigroup’s head of growth equity, there are signs that growth IPOs may be returning.

“One indicator is the recent burst of convertible bond sales by listed tech companies,” Davis explained. “That market has opened up dramatically in the last six weeks — and that’s a very positive sign.”

Beyond raising capital, a public listing can be strategically advantageous, especially in mergers and acquisitions.

“It helps to have a publicly traded, liquid, and independently valued currency,” Davis added. “That gives companies real leverage in acquisitions and expansion.”


Keeping the Door Open

Among the rising stars in the private tech space is Kore.ai, an AI software firm and Citigroup client. The company, valued at US$800 million following a US$150 million investment round in 2023 (which included Nvidia), is keeping its IPO options open.

“We’re still evaluating the right growth path,” said DK Sharma, chief operating officer of Kore.ai. “It might be an acquisition, or it might be an IPO — but for now, our focus is building strength and scale on top of our current momentum.”


As secondary markets thrive, the pipeline of IPO-ready companies is only getting deeper — and when the public market window opens fully, investors could see a flurry of tech listings not seen since the post-pandemic boom.

“The coil is winding,” Collmer said. “It’s only a matter of time before it springs.”

Thank you

Mermaid Maritime PCL: Strong Bullish Breakout Signals Potential 90% Upside

Comprehensive Stock Analysis: Alibaba Health, HK Exchanges, CJ Logistics, Mermaid Maritime Comprehensive Stock Analysis: Alibaba Health, HK Exchanges, CJ Logistics, and Mermaid Maritime Date: February 13, 2025 Broker: CGS International Securities Alibaba Health Information...

“Telco Shake-Up? StarHub and M1 Merger Speculation Heats Up Amid Payment Deferrals”

“Telco Shake-Up? StarHub and M1 Merger Speculation Heats Up Amid Payment Deferrals” Speculation is mounting over a potential merger between Singapore telcos StarHub and M1, as both companies defer their 700 MHz spectrum payment...

VISEN Pharmaceuticals’ HK$672 Million IPO: Pioneering Endocrine Therapies in Hong Kong’s Biotech Boom

​Visen Pharmaceuticals, a biopharmaceutical company specializing in endocrinology treatments in China, is set to list on the Hong Kong Stock Exchange under the ticker 02561.HK. The IPO is scheduled for March 21, 2025, aiming...